Rengan Ramesh, Paty Philip B, Wong W Douglas, Guillem Jose G, Weiser Martin, Temple Larissa, Saltz Leonard, Minsky Bruce D
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Clin Colorectal Cancer. 2006 Mar;5(6):413-21. doi: 10.3816/CCC.2006.n.012.
The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma.
Between April 1988 and December 1996, 36 (cT2, n=9; cT3, n=27) patients with rectal adenocarcinoma were enrolled on a phase I/II trial of preoperative RT followed by surgical resection. All patients had distal tumors that were clinically judged to require an abdominoperineal resection and received preoperative RT (50.4 Gy) followed by surgery. The median follow-up was 94.5 months (range, 4-187 months).
Of the 35 patients in this study who underwent resection, 77% were able to undergo sphincter preservation after preoperative RT. The pathologic complete response rate for these patients was 14%. The 10-year rates of overall survival and local failure for patients undergoing sphincter preservation were 54% and 21%, respectively. The 10-year local failure was 26% in patients with cT3 disease who underwent sphincter preservation. All local failures in this study occurred in patients with cT3 disease undergoing sphincter preservation; however, none of the patients with cT3 disease that was downstaged by preoperative RT experienced local failure. In contrast, 10-year local failure was 67% in the patients with cT3 disease that was not downstaged by RT. Sphincter function was good or excellent in 85% of patients at the time of last follow-up.
This approach provides excellent long-term results in all patients with cT2 disease and those with cT3 disease that is downstaged by RT. However, patients with cT3 disease that is not downstaged by RT have an increased risk of local failure. These data underscore the impact of tumor response to radiation on long-term oncologic outcome.
本研究的主要目的是确定术前放疗(RT)联合手术切除治疗低位直肠腺癌时保留括约肌的长期疗效。
1988年4月至1996年12月期间,36例(cT2,n = 9;cT3,n = 27)直肠腺癌患者参加了一项术前RT联合手术切除的I/II期试验。所有患者均患有低位肿瘤,临床判断需要行腹会阴联合切除术,并接受术前RT(50.4 Gy),随后进行手术。中位随访时间为94.5个月(范围4 - 187个月)。
本研究中35例接受手术切除的患者,77%在术前RT后能够保留括约肌。这些患者的病理完全缓解率为14%。保留括约肌患者的10年总生存率和局部复发率分别为54%和21%。保留括约肌的cT3期疾病患者10年局部复发率为26%。本研究中所有局部复发均发生在保留括约肌的cT3期疾病患者中;然而,术前RT使分期降低的cT3期疾病患者无一例发生局部复发。相比之下,未因RT使分期降低的cT3期疾病患者10年局部复发率为67%。在最后一次随访时,85%的患者括约肌功能良好或优秀。
这种方法在所有cT2期疾病患者以及术前RT使分期降低的cT3期疾病患者中均能提供良好的长期疗效。然而,未因RT使分期降低的cT3期疾病患者局部复发风险增加。这些数据强调了肿瘤对放疗的反应对长期肿瘤学结局的影响。